Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6626997 | 0.93 | MPO (0.49) | GPR119CYP3A4CYP2C9DHODHNR1H2 | |
| SCHEMBL17812870 | 0.90 | HTR2A (0.50) | GPR119CYP3A4CYP2C9DHODHABHD6 | |
| SCHEMBL28720577 | 0.89 | GPR119 (0.48) | GPR119CYP3A4CYP2C9DHODHABHD6 | |
| SCHEMBL19689708 | 0.87 | GPR119 (0.47) | GPR119CYP3A4CYP2C9DHODHABHD6 | |
| SCHEMBL6646436 | 0.86 | KDM4E (0.54) | CYP3A4CYP2C9ABHD6NOTUMHTR2A | |
| SCHEMBL6856385 | 0.83 | MPO (0.43) | NOTUMNR1H2MPOBRD4CHRM4 | |
| SCHEMBL22482270 | 0.82 | PDK1 (0.57) | GPR119CYP3A4CYP2C9MPOBRD4 | |
| SCHEMBL1058537 | 0.82 | NR1H2 (0.62) | GPR119CYP3A4CYP2C9DHODHABHD6 | |
| SCHEMBL30147443 | 0.82 | NOTUM (0.65) | GPR119DHODHABHD6NOTUMBRD4 | |
| SCHEMBL16603725 | 0.82 | NOTUM (0.65) | GPR119DHODHABHD6NOTUMBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641881-B | 1-tetrahydropyranyl carbonyl-2, 3-dihydro-1H-indole compounds for use in the treatment of cancer | 伊莱利利公司 | 2022-01-07 | — | — | CN | disclosed |
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3468965-B1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | LILLY CO ELI (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY | 2019-05-30 | — | — | US | disclosed |
| EP-3468965-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | Eli Lilly and Company (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9872853-B2 | 2,3-dihydro-1H-indole compounds | ELI LILLY AND COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY | 2017-12-14 | — | — | US | disclosed |
| WO-2017213919-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | MCL1, IDO1, GLI1 | GPR119 120/4885CYP3A4 1746/4885CYP2C9 2557/4885 |
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | MCL1, FOXM1, IDO1 | GPR119 266/4885CYP3A4 1832/4885CYP2C9 2648/4885 |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | MCL1, IDO1, IDO2 | GPR119 344/4885CYP3A4 1506/4885CYP2C9 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.